,

Press Room

UK and Ireland News


20 May, 2021
New Analysis Reinforces Cost-Effectiveness of the Oncotype DX Breast Recurrence Score® Test in Node-Positive Early-Stage Breast Cancer

25 March, 2021
New NCCN Breast Cancer Guidelines Recognise Oncotype DX Breast Recurrence Score® as the “Preferred” and Only Multigene Test to Predict Chemotherapy Benefit in Node-positive Early-stage Breast Cancer

9 December, 2020
RxPONDER study results demonstrate that the Oncotype DX® Test can now spare chemotherapy use in the majority of women with node-positive early-stage breast cancer

2 October 2020
New real-world evidence further demonstrates the Oncotype DX Breast Recurrence Score® Test’s clinical utility, beyond clinical risk factors, in guiding chemotherapy treatment decisions in patients with early-stage breast cancer

29 May 2020
New data and society guidelines support value of Oncotype DX Breast Recurrence Score® Test in guiding neoadjuvant treatment decisions for newly diagnosed patients

14 May 2020
New Oncotype DX® real-world evidence shows for the first time the practice-changing impact of TAILORx results


2019 Archive
2018 Archive
2017 Archive
2016 Archive
Making cancer care smarter.™